Titre : | Postmarketing surveillance of abuse liability of sibutramine |
Titre traduit : | (Surveillance post-marketing du potentiel d'abus de la sibutramine) |
Auteurs : | C. L. ARFKEN ; C. R. SCHUSTER ; C. E. JOHANSON |
Type de document : | Périodique |
Année de publication : | 2003 |
Format : | 169-173 / tabl. |
Note générale : |
Drug and Alcohol Dependence, 2003, 69, (2), 169-173 |
Langues: | Anglais |
Discipline : | EPI (Epidémiologie / Epidemiology) |
Mots-clés : |
Thésaurus mots-clés MEDICAMENTS ; ANOREXIGENES ; POTENTIEL ADDICTIF ; ABUS ; ETUDE LONGITUDINALE |
Résumé : |
ENGLISH : The abuse liability of medications is a growing concern as the number of newly approved psychoactive medications increases. Postmarketing surveillance can assist in determining abuse liability, but strategies are not well-defined for medications believed to be at low abuse risk. Using a newly approved medication (sibutramine-an anorectic drug), a novel approach to postmarketing abuse surveillance was introduced. A one-page anonymous questionnaire covering sibutramine, a scheduled anorectic drug (phentermine), and a fabricated name was added to the intake process of 58 treatment programs. From the 8780 completed questionnaires, 8.8% had heard of sibutramine and phentermine. For continued use to get high (a proxy for abuse), the rate for sibutramine was lower than for phentermine (0.6 vs. 2.2%, McNemar's c2 = 110.45, P |
Note de contenu : | tabl. |
Domaine : | Autres substances / Other substances |
Refs biblio. : | 13 |
Affiliation : |
Dept. Psychiatry Behav. Neurosci., Addic. Res. Inst., Wayne State Univ., 2761 E. Jefferson, Detroit, MI 48207 Etats-Unis. United States. |
Numéro Toxibase : | 804262 |
Centre Emetteur : | 08 CAS Strasbourg |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil